Roche Plays Down Reliance On TIGIT And Alzheimer’s Drugs For Growth
Company Boasts 51 Late-Stage Candidates
Pharma chief Bill Anderson was optimistic about growth prospects, and downplayed Roche’s reliance on two near-term readouts at an investor day in London.
You may also be interested in...
Once heralded with optimism, the class of anti-TIGIT molecules has since fallen out of favor, plagued by a succession of disappointing findings.
Every year, Roche looks at “more than 1,000 companies and 99.9% of the time, we say no," says CEO Thomas Schinecker, though he stressed that the Swiss group is open to deals of any size.
Drug makers have sought to branch into new frontiers of drug development in areas like cancers and neurology, but not all of them have been success stories. Here, Scrip looks at some of the more notable clinical trial misses of last year.